ArticleJournal of cancer research and clinical oncology2015
Polymorphisms of monocarboxylate transporter genes are associated with clinical outcomes in patients with colorectal cancer.
Article in Journal of cancer research and clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Associations Between Genetic Variants inInternational journal of molecular sciences · 2025Article
- Article
- Review
- Gene polymorphisms and thyroid hormone signaling: implication for the treatment of hypothyroidism.Endocrine · 2024Review
- What can we learn about acid-base transporters in cancer from studying somatic mutations in their genes?Pflugers Archiv : European journal of physiology · 2024Review
- Unraveling the gut health puzzle: exploring the mechanisms of butyrate and the potential of High-Amylose Maize Starch Butyrate (HAMSB) in alleviating colorectal disturbances.Frontiers in nutrition · 2024Review
- Role of Human Monocarboxylate Transporter 1 (hMCT1) and 4 (hMCT4) in Tumor Cells and the Tumor Microenvironment.Cancer management and research · 2023Review
- Short Chain Fatty Acid Metabolism in Relation to Gut Microbiota and Genetic Variability.Nutrients · 2022Review
- BSG (CD147) Serum Level and Genetic Variants Are Associated with Overall Survival in Acute Myeloid Leukaemia.Journal of clinical medicine · 2022Article
- Pharmacogenomics with red cells: a model to study protein variants of drug transporter genes.Vox sanguinis · 2021Review
- Article
- The Drug of Abuse Gamma-Hydroxybutyric Acid Exhibits Tissue-Specific Nonlinear Distribution.The AAPS journal · 2017Article
- Racial disparity in metabolic regulation of cancer.Frontiers in bioscience (Landmark edition) · 2017Review
- Review
- Heterozygous Monocarboxylate Transporter 1 (MCT1, SLC16A1) Deficiency as a Cause of Recurrent Ketoacidosis.JIMD reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrevious studies have demonstrated that monocarboxylate transporters (MCTs) play important roles in the development and progression of many cancers. The purpose of this study was to assess the effects of single-nucleotide polymorphisms (SNPs) of MCT genes on prognosis of colorectal cancer (CRC) patients. PATIENTS AND
methodsNine functional SNPs in three MCT genes (MCT1, MCT2 and MCT4) were selected and genotyped using Sequenom iPLEX genotyping system in 697 Chinese CRC patients receiving surgery. Multivariate Cox proportional hazards model and Kaplan-Meier curve were used for the prognostic analysis.
resultsOne SNP (MCT1: rs1049434/exon) was significantly associated with overall survival of CRC patients (HR 0.74; P = 0.046). Two other SNPs (MCT1: rs60844753/5' near gene and MCT2: rs995343/intron) exhibited associations with recurrence-free survival of CRC patients (HR 0.67; P = 0.078 and HR 0.74; P = 0.036, respectively). Our study also showed that MCT1 rs1049434, rs60844753 and MCT2 rs995343 SNPs had a cumulative effect on CRC recurrence-free survival (P for trend 0.011). Those who carrying three unfavorable genotypes (WW for all SNPs) had a 2.06-fold increased risk of recurrence compared with patients carrying no unfavorable genotypes (P = 0.016). Moreover, we found that patients carrying no <2 risk genotypes showed significant OS and RFS benefits from adjuvant chemotherapy.
conclusionsOur findings suggest that SNPs in MCT1 and MCT2 genes may affect clinical outcomes and can be used to predict the response to adjuvant chemotherapy in CRC patients who received surgical treatment once validated in future study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.